Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"STA Pharmaceutical","sponsor":"Qualigen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Qualigen Therapeutics Engages STA Pharmaceutical as GMP Manufacturer of AS1411 for Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by STA Pharmaceutical

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Qualigen Therapeutics has signed a contract with STA Pharmaceutical, a subsidiary of WuXi AppTec, for GMP production of AS1411, Qualigen's lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials.

            Lead Product(s): AS1411

            Therapeutic Area: Infections and Infectious Diseases Product Name: AS1411

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Qualigen Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 05, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY